Data in Brief (Aug 2020)

Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8–13) analog

  • Élie Besserer-Offroy,
  • Pascal Tétreault,
  • Rebecca L Brouillette,
  • Adeline René,
  • Alexandre Murza,
  • Roberto Fanelli,
  • Karyn Kirby,
  • Alexandre Parent,
  • Isabelle Dubuc,
  • Nicolas Beaudet,
  • Jérôme Côté,
  • Jean-Michel Longpré,
  • Jean Martinez,
  • Florine Cavelier,
  • Philippe Sarret

Journal volume & issue
Vol. 31
p. 105884

Abstract

Read online

Neurotensin (NT) is a tridecapeptide displaying interesting antinociceptive properties through its action on its receptors, NTS1 and NTS2. Neurotensin-like compounds have been shown to exert better antinociceptive properties than morphine at equimolar doses. In this article, we characterized the molecular effects of a novel neurotensin (8–13) (NT(8–13)) analog containing an unnatural amino acid. This compound, named JMV2009, displays a Silaproline in position 10 in replacement of a proline in the native NT(8–13). We first examined the binding affinities of this novel NT(8–13) derivative at both NTS1 and NTS2 receptor sites by performing competitive displacement of iodinated NT on purified cell membranes. Then, we evaluated the ability of JMV2009 to activate NTS1-related G proteins as well as to promote the recruitment of β-arrestins 1 and 2 by using BRET-based cellular assays in live cells. We next assessed its ability to induce p42/p44 MAPK phosphorylation and NT receptors internalization using western blot and cell-surface ELISA, respectively. Finally, we determined the in vitro plasma stability of this NT derivative. This article is associated with the original article “Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog” published in European Journal of Pharmacology [1]. The reader is directed to the associated article for results interpretation, comments, and discussion.

Keywords